Back to Results

Profound Medical Corp (PROF)

Featured in High-Beta Stocks

Profound Medical Corp. is a commercial-stage medical device company listed on NASDAQ under the ticker PROF. The company develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for image-guided ablation of diseased tissue. Its lead platform, TULSA-PRO, uses MRI, robotically driven transurethral sweeping action, thermal ultrasound, and closed-loop temperature feedback to treat whole-gland or physician-defined regions of malignant or benign prostate tissue. Profound Medical also offers Sonalleve, an MRI- and thermometry-based system used in the treatment of uterine fibroids, adenomyotic tissue, certain bone metastases, osteoid osteoma, and benign tumors. The company operates in Canada, Germany, the United States, China, and Finland and is headquartered in Mississauga, Canada.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-PROF
$7.11
4.7% Upside
Fair
$11.14
64.1% Upside
Bargain
Fair
—
—
—
0.0%
August 6, 2026
-6.4x
4.2x
13.3x
248.1 M
207.9 M
2.9%
95.6%
-3.6
—
99.4%
Send a message
Valuation • Fair Value

Profound Medical Corp (NASDAQ-PROF) Fair Value by Valuation Model

Compare the primary fair value estimate for Profound Medical Corp (NASDAQ-PROF) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$7.11

Estimated upside of 4.7% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$7.78

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$5.42

Earnings power value estimate.

Comps Fair Value

$6.83

Comparable-company valuation reference.

Analyst Price Target

$11.14

Analysts imply upside of 64.1%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Profound Medical Corp (NASDAQ-PROF) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Profound Medical Corp (NASDAQ-PROF)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

18.814 M

Current operating scale indicator.

Revenue Forecast

24.828 M

Forward revenue estimate.

EBITDA

-37.612 M

Current operating profitability reference.

EBITDA Forecast

-28.007 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Profound Medical Corp (NASDAQ-PROF) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Profound Medical Corp (NASDAQ-PROF)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-1.60

Higher caution zone on this screen.

Altman Z-Score

-3.6

Lower score that deserves closer risk review.

FCF / Net Income

99.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Profound Medical Corp (NASDAQ-PROF). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Profound Medical Corp (NASDAQ-PROF)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 6, 2026

Days to Earnings

16

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Profound Medical Corp (NASDAQ-PROF), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Profound Medical Corp (NASDAQ-PROF) Stock Forecast & Technical Outlook

Review Profound Medical Corp (NASDAQ-PROF) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Profound Medical Corp (NASDAQ-PROF) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Profound Medical Corp (NASDAQ-PROF) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Profound Medical Corp (NASDAQ-PROF) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Profound Medical Corp (NASDAQ-PROF) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Profound Medical Corp (NASDAQ-PROF) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Profound Medical Corp (NASDAQ-PROF)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Profound Medical Corp (NASDAQ-PROF) has a Strong Buy consensus, with 4 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 4
Hold 0
Sell 0
FAQ • Fast Investor Answers

Profound Medical Corp (NASDAQ-PROF) Stock FAQ

Quick answers about Profound Medical Corp (NASDAQ-PROF) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$7.11
Estimated upside 4.7%
Valuation Rating
Undervalued
Estimated upside of 4.7%
Analyst Target
$11.14
Implied upside 64.1%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Profound Medical Corp (NASDAQ-PROF) is $7.11. This implies an estimated upside of 4.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 4.7% versus the current market price.

The available analyst price target for Profound Medical Corp (NASDAQ-PROF) is $11.14. The analyst target implies estimated upside of 64.1%.

The current financial health read for Profound Medical Corp (NASDAQ-PROF) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Profound Medical Corp (NASDAQ-PROF) is August 6, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Profound Medical Corp (NASDAQ-PROF) is -6.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Profound Medical Corp is 248.1 M.

The current enterprise value listed for Profound Medical Corp is 207.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Profound Medical Corp is NASDAQ-PROF, and the stock is listed on NASDAQ.

Profound Medical Corp (NASDAQ-PROF) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Profound Medical Corp is 2.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Profound Medical Corp is 95.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NASDAQ View more

Intuitive Surgical Inc (ISRG) Intuitive Surgical Inc (ISRG)
Medline Inc (MDLN) Medline Inc (MDLN)
IDEXX Laboratories Inc (IDXX) IDEXX Laboratories Inc (IDXX)
DexCom Inc (DXCM) DexCom Inc (DXCM)
GE HealthCare Technologies Inc (GEHC) GE HealthCare Technologies Inc (GEHC)
Cooper Companies Inc (COO) Cooper Companies Inc (COO)
Align Technology Inc (ALGN) Align Technology Inc (ALGN)
Insulet Corporation (PODD) Insulet Corporation (PODD)
Lantheus Holdings Inc (LNTH) Lantheus Holdings Inc (LNTH)
MiniMed Group Inc (MMED) MiniMed Group Inc (MMED)
Merit Medical Systems Inc (MMSI) Merit Medical Systems Inc (MMSI)
LivaNova PLC (LIVN) LivaNova PLC (LIVN)
ICU Medical Inc (ICUI) ICU Medical Inc (ICUI)
IRhythm Technologies Inc (IRTC) IRhythm Technologies Inc (IRTC)
Establishment Labs Holdings Inc (ESTA) Establishment Labs Holdings Inc (ESTA)
Dentsply Sirona Inc (XRAY) Dentsply Sirona Inc (XRAY)
TransMedics Group Inc (TMDX) TransMedics Group Inc (TMDX)
LeMaitre Vascular Inc (LMAT) LeMaitre Vascular Inc (LMAT)
Neogen Corporation (NEOG) Neogen Corporation (NEOG)
Axogen Inc (AXGN) Axogen Inc (AXGN)
Omnicell Inc (OMCL) Omnicell Inc (OMCL)
Pulse Biosciences Inc (PLSE) Pulse Biosciences Inc (PLSE)
UFP Technologies Inc (UFPT) UFP Technologies Inc (UFPT)
Novocure Ltd (NVCR) Novocure Ltd (NVCR)